Ultragenyx Pharmaceutical (RARE) Projected to Post Quarterly Earnings on Thursday

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) is expected to post its quarterly earnings results after the market closes on Thursday, February 13th. Analysts expect Ultragenyx Pharmaceutical to post earnings of ($1.32) per share and revenue of $158.71 million for the quarter. Parties that are interested in registering for the company's conference call can do so using this link.

Ultragenyx Pharmaceutical Stock Down 2.7 %

Shares of Ultragenyx Pharmaceutical stock traded down $1.20 during trading hours on Tuesday, reaching $43.58. 571,652 shares of the company's stock were exchanged, compared to its average volume of 911,006. Ultragenyx Pharmaceutical has a 1 year low of $37.02 and a 1 year high of $60.37. The company has a market capitalization of $4.02 billion, a P/E ratio of -6.74 and a beta of 0.60. The business has a fifty day moving average of $43.94 and a two-hundred day moving average of $49.65.

Insider Transactions at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the business's stock in a transaction on Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the transaction, the chief executive officer now directly owns 2,183,985 shares of the company's stock, valued at approximately $92,229,686.55. The trade was a 0.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders own 5.80% of the company's stock.

Analyst Upgrades and Downgrades

RARE has been the subject of a number of analyst reports. TD Cowen upped their price objective on shares of Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a "buy" rating in a report on Monday, October 21st. Wells Fargo & Company upped their price objective on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an "overweight" rating in a report on Friday, December 20th. HC Wainwright reissued a "buy" rating and issued a $95.00 price objective on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. Piper Sandler increased their target price on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the stock an "overweight" rating in a research note on Monday, January 13th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $118.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Wednesday, January 22nd. One analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat.com, Ultragenyx Pharmaceutical presently has a consensus rating of "Moderate Buy" and a consensus price target of $92.43.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.